Core Insights - Vera Therapeutics is a biopharmaceutical company focused on developing treatments for serious diseases, with a current stock price of $33.33 and a price target set by H.C. Wainwright at $90, indicating a potential increase of about 172% [1][5] - The stock recently surged by 13%, influenced by a positive research note from Cantor Fitzgerald's analyst, who reiterated a buy recommendation and set a price target of $100, over three times the current share price [2][5] - The market for IgA Nephropathy treatments is identified as a multi-billion-dollar opportunity, which could significantly boost Vera's revenue if successful [3][5] Stock Performance - VERA's stock has shown volatility, trading between $28.81 and $34.07 recently, with a one-year high of $51.27 and a low of $18.53 [4] - The company's market capitalization is approximately $2.13 billion, indicating its standing in the biopharmaceutical industry [4] - The trading volume of 3,189,748 shares reflects active investor interest in VERA's stock [4]